See the pattern, not just the headline.

Pathos AI raises $237 million to scale its oncology platform and clinical pipeline

Pathos AI closed a $237 million Series E round at an approximately $3 billion post-money valuation, led by Bristol Myers Squibb. The company says the capital will expand its Foundry AI platform and advance four clinical-stage oncology assets, including preparation for a registrational study of JSKN-016.